. "Appendix D-13: The Prospects for Immunizing Against Rotavirus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
Rodriguez, W.J., H.W.Kim, C.D.Brandt, B.Bise, A.Z.Kapikian, R.M. Chanock, G.Curlin, and R.H.Parrott. 1980. Rotavirus gastroenteritis in the Washington, D.C., area. Am. J. Dis. Child. 134(8):777–779.
Sack, D.A., A.M.A.K.Chowdhury, A.Eusof, M.A.Ali, M.H.Merson, S. Islam, R.E.Black, and K.H.Brown. 1978. Oral hydration in rotavirus diarrhoea: A double blind comparison of sucrose with glucose electrolyte solution. Lancet II:280–283.
Sato, K., Y.Inaba, T.Shinozaki, R.Fujii, and M.Matumoto. 1981. Isolation of human rotavirus in cell cultures: Brief report. Arch. Virol. 69(2):155–160.
Soenarto, Y., T.Sabodo, R.Ridho, H.Alrasjid, J.E.Rohde, H.C.Bugg, G.L.Barnes, and R.F.Bishop. 1981. Acute diarrhea and rotavirus infection in newborn babies and children in Yogyakarta, Indonesia, from June 1978–June 1979. J. Clin. Microbiol. 14:123–129.
Urasawa, T., S.Urasawa, and K.Taniguchi. 1981. Sequential passages of human rotavirus in MA-104 cells. Microbiol. Immunol. 25(10):1025–1035.
Vesikari, T., E.Isolauri, A.Delem, E.O’Hondt, F.E.André, and G.Zissis. 1983. Immunogenicity and safety of live attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet II:807–811.
Vesikari, T., E.Isolauri, E.O’Hondt, A.Delem, F.E.André, and G. Zissis. 1984. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet I:977–981.
Vesikari, T., E.Isolauri, F.E.André, E.d’Hondt, A.Delem, G.Zissis, G.Beards, and T.H.Flewett. 1985. Protection of infants against the human rotavirus diarrhea by the RIT 4237 live attenuated bovine rotavirus vaccine. Pp. 369–372 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A.Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Habor Laboratories.
Wyatt, R.G., C.A.Mebus, R.H.Yolken, A.R.Kalica, H.D.James, A.Z. Kapikian, and R.M.Chanock. 1979. Rotaviral immunity in gnotobiotic calves: Heterologous resistance to human virus induced by bovine virus. Science 203 (4380):548–550.
Wyatt, R.G., K.W.Thiel. L.J.Saif, A.R.Kalica, H.B.Greenberg, A.Z. Kapikian, and R.M.Chanock. 1980. Human rotavirus type 2: Cultivation in vitro. Science 207(4427):189–191.
Wyatt, R.G., H.B.Greenberg, W.D.James, A.L.Pittman, A.R.Kalica, J. Flores, R.M.Chanock, and A.Z.Kapikian. 1982. Definition of human rotavirus serotypes by plaque reduction assay. Infect. Immun. 37 (1):110–115.
Zissis, G., J.P.Lambert, P.Marbehant, D.Marissens, M.Lobmann, P. Charlier, A.Delem, and N.Zygraich. 1983. Protection studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. J. Infect. Dis. 148(6):1061–1068.